NASDAQ:BDTX

Black Diamond Therapeutics Q4 2024 Earnings Results & Report

Black Diamond Therapeutics logo
$1.44 -0.09 (-5.88%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.04%)
As of 11/17/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics beat analyst earnings expectations in its Q4 2024 results, released March 6, 2025. The company reported EPS of -$0.28 versus the -$0.31 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Black Diamond Therapeutics EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Black Diamond Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Black Diamond Therapeutics Q4 2024 Earnings FAQ

Black Diamond Therapeutics (NASDAQ:BDTX) reported earnings of -$0.28 per share for Q4 2024, beating the consensus estimate of -$0.31. The report was announced on Thursday, March 6, 2025.

Black Diamond Therapeutics Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Black Diamond Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email.

About Black Diamond Therapeutics

Black Diamond Therapeutics (NASDAQ:BDTX) is a clinical-stage biotechnology company focused on developing precision medicines for people with genetically defined cancers. The company uses its discovery platform to identify cancer-causing mutations and develop small-molecule therapies designed to target them.

Its pipeline has included BDTX-1535, an investigational inhibitor designed to target certain EGFR alterations in cancers such as non-small cell lung cancer. The company’s candidates are in clinical development; it does not have an approved commercial product.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics conducts research and clinical development with the goal of addressing cancer mutations that may not be served by existing treatments.

View Black Diamond Therapeutics Profile